Future development of nanoparticle drug-delivery systems should place greater emphasis on personalized nanomedicine, structured around a “patient stratification–vector matching–dynamic evaluation” workflow: nanocarriers are selected according to tumor molecular markers and receptor expression profiles (e.g., PSMA, uPAR, EphA2) to achieve precise targeting and efficient delivery [329]. The gene discussed is EPHA2; the disease is neoplasm.